Aquaporin gene therapy corrects Sjögren’s syndrome phenotype in mice

Zhennan Lai,Hongen Yin,Javier Cabrera-Pérez,Maria C. Guimaro,Sandra Afione,Drew G. Michael,Patricia Glenton,Ankur Patel,William D. Swaim,Changyu Zheng,Cuong Q. Nguyen,Fred Nyberg,John A. Chiorini
DOI: https://doi.org/10.1073/pnas.1601992113
IF: 11.1
2016-05-02
Proceedings of the National Academy of Sciences
Abstract:Significance Recent reports of increases in the prevalence and incidence of autoimmune diseases make this disease group a pressing public health concern. Patients suffering from Sjögren’s syndrome experience debilitating oral and ocular dryness due to dysfunction within the salivary and lacrimal glands. Due to our lack of knowledge regarding the underlying mechanisms, no effective treatments are available and affected organs gradually degenerate. In this study, we identify the loss of water permeability as a mechanism associated with xerostomia in a subset of patients. We demonstrate that a novel therapy, aquaporin 1 replacement, can increase the water permeability of the gland and restore fluid movement while relieving the dry mouth and eye phenotypes associated with this disease in addition to disease-associated inflammation.
What problem does this paper attempt to address?